S&C Advises Amgen in $1.9 Billion Acquisition of Five Prime Therapeutics

March 4, 2021

Amgen has agreed to acquire Five Prime Therapeutics in a deal valued at approximately $1.9 billion. The deal is expected to close in the second quarter of 2021.
A biotechnology pioneer since 1980, Amgen is one of the world's largest independent biotechnology companies. Amgen uses tools such as advanced human genetics to treat patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Five Prime Therapeutics is a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies.
The S&C team advising on the transaction includes Frank Aquila and associates Mimi Wu, Chiyel Hayles and Elizabeth Cheung. Nader Mousavi and associate Rachel Yu advised on intellectual property matters related to the transaction. Heather Coleman advised on executive compensation matters. S&C also advised on tax-related matters.